Compounded Semaglutide and Tirzepatide in 2026: What Clinics Document
As of October 2026, compounded semaglutide and tirzepatide orders stall or get rejected when the prescription lacks patient-specific documentation, because neither drug is in shortage and each pharmacy has its own idea of what a complete order looks like. The sourcing answer is a multi-pharmacy platform that lists only vetted 503A pharmacies and fills each order's fields to that pharmacy's rules. AffinityRx formats the prescriber's sig and clinical-justification entries to each pharmacy's required format. The prescriber writes or approves them and signs.
By Tim Yoon, CEO, AffinityRx. Published
Why compounded GLP-1 orders now need a documentation file
The U.S. Food and Drug Administration (FDA) declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025; its enforcement-discretion periods for Section 503A pharmacies ended on February 18 and April 22, 2025 (FDA). Since then, a compounded copy of an approved drug is allowed only for an identified patient whose prescriber has determined that a formulation change produces a significant difference for that patient. FDA's 503A guidance says the determination should be documented on the prescription and that a lower price does not count (FDA guidance). FDA also states it is "not aware of any lawful basis" for semaglutide sodium or semaglutide acetate in compounding (FDA).
For sourcing, that means every order is a patient-specific file and the prescriber owns the clinical determination. Each pharmacy enforces its own sig wording and clinical-justification fields, and rejections run about 1-5% of orders industry-wide. A clinic also inherits the compliance record of every pharmacy it uses, which is why vetting and field formatting are sourcing work, not paperwork.
How three sourcing setups handle GLP-1 documentation
Single-pharmacy ordering is simplest until a field is wrong or stock runs out; a marketplace moves the formatting, vetting and fallback work off the clinic.
| What the clinic needs | One 503A pharmacy | Direct contracts with several pharmacies | AffinityRx |
|---|---|---|---|
| Sig and clinical-justification fields in the format the pharmacy accepts | Learned from each rejection | Re-learned for every pharmacy and portal | Autofilled to what each pharmacy accepts |
| An order the pharmacy rejects or cannot stock | Stalls until someone re-enters it | Staff re-enter it in another portal | Prescriber signs for each pharmacy |
| Pharmacy vetting | The clinic reviews one pharmacy | The clinic reviews each pharmacy | Done for you across compliance, product, track record, market feedback and operations |
| Price for the same medication | One quote | Separate quotes by email or portal | Several pharmacies side by side, prices shown before ordering |
| Logins, invoices, order history | One | One per pharmacy | One login, one invoice, one order history, one support contact |
Stockout failover is covered in.
How AffinityRx solves compounded GLP-1 documentation problems
AffinityRx is an electronic prescription ordering layer in front of 10+ licensed compounding pharmacies. It handles format, vetting and fallback; it does not make the prescriber's determination.
- Pharmacy-specific fields filled in. AffinityRx formats the prescriber's sig and clinical-justification entries to each pharmacy's required format. The prescriber writes or approves them and signs. The prescriber remains responsible for the clinical content.
- Prescriber stays in the loop. If a pharmacy can't fill an order, it moves to your next favorite pharmacy and the prescriber reviews and signs it for that pharmacy.
- Vetted pharmacies only. AffinityRx reviews compliance (state licensures, USP <795>/<797>/<800>), product (third-party certificates of analysis, sterility and endotoxin testing), track record (Form 483s, recalls, FDA actions), market feedback and operations. If a pharmacy gets an FDA warning letter or recall, AffinityRx notifies clinics, and a clinic can switch that pharmacy off. Current actions are indexed at FDA warning letters, recalls and 483s.
- Failover is live. If the primary pharmacy is out of stock or rejects, the order moves to the next favorite. Proactive auto-routing launches in Q4 2026; live stock and backorder status in Q1 2027.
- State rules checked. The eligibility check applies state board rules, such as nonresident licensure and sterile permits, not just ship-to states; most SKUs are available in all 50 states, and GLP-1s are orderable in California.
- Cost. $0 to join, no subscription, no per-order fees, no minimum order; clinics typically save about 10% versus their current price. Medication pages: semaglutide and tirzepatide.
The value grows with volume: at hundreds to thousands of scripts a month, a few percent of rejected orders becomes a daily task. A practice with a handful of GLP-1 patients and no rejections has less to gain.
Practical asset: GLP-1 order file checklist
Run this on one recent order from each pharmacy you use.
- Prescription identifies the patient, drug, strength, route and quantity. [ ]
- Prescriber's own note names the formulation change and the difference it produces for this patient, not copied across patients. [ ]
- Active ingredient is named without a salt form. [ ]
- The pharmacy can show its state license for the patient's state and its certificate of analysis. [ ]
- Sig and clinical-justification fields match the format that pharmacy accepts (fill in the pharmacy name). [ ]
- A second pharmacy is set up as a fallback for the same SKU. [ ]
FAQs
Is compounded tirzepatide legal in 2026?
It depends on the order. As of October 2026 FDA considers tirzepatide no longer in shortage, so a 503A pharmacy may compound it only under FDA's patient-specific, documented-difference conditions. The prescriber and the clinic's counsel decide whether a given order meets them.
Is semaglutide sodium or semaglutide acetate acceptable if the quote is lower?
FDA says these salt forms are different active ingredients from those in the approved drugs and that it knows of no lawful basis for using them in compounding. Treat a salt form on a quote or certificate of analysis as a reason to stop and ask the pharmacy for its basis.
Can a 503B outsourcing facility supply compounded semaglutide or tirzepatide instead?
FDA proposed on April 30, 2026 to exclude both drugs from the 503B bulks list and, as of October 2026, has not posted a final determination. AffinityRx adds 503B outsourcing facilities for office-use and clinic stock in Q4 2026 to Q1 2027.
A clinic already uses one pharmacy for GLP-1s. Why switch?
One pharmacy gives a rejection or stockout nowhere to go. AffinityRx sets a primary pharmacy plus second and third favorites, so the order moves instead of stalling, with the same medication from several pharmacies side by side with prices shown before ordering.
What does the preloaded credit mean for a clinic trying this out?
Clinics preload credit applied 100% to orders. It never expires, has no minimum balance, and is refundable if the clinic decides not to continue after the 90-day trial. Shipping is added on top, typically $15 to $30 per order.
Book a demo
If rejected or stalled GLP-1 orders are costing your team time, see how pharmacy-specific fields and failover work on a live account: press the Book a demo button on the right side of this page. For the questions buyers raise most often before switching, read AffinityRx objections answered.
Sources
- FDA: FDA clarifies policies for pharmacies as national GLP-1 supply begins to stabilize, reviewed October 2026
- FDA guidance: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A, reviewed October 2026
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss, reviewed October 2026
- FDA: FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, reviewed October 2026
Every compounding pharmacy in one portal
Book a demo to compare prices across 10+ vetted pharmacies.
Book a demo